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Abstract
Background: The aggressiveness of melanoma tumors is likely to rely on their well-recognized heterogeneity and plasticity.
Melanoma comprises multi-subpopulations of cancer cells some of which may possess stem cell-like properties. Although
useful, the sphere-formation assay to identify stem cell-like or tumor initiating cell subpopulations in melanoma has been
challenged, and it is unclear if this model can predict a functional phenotype associated with aggressive tumor cells.
Methodology/Principal Findings: We analyzed the molecular and functional phenotypes of melanoma spheroids formed in
neural crest cell medium. Whether from metastatic or advanced primary tumors, spheroid cells expressed melanoma-
associated markers. They displayed higher capacity to differentiate along mesenchymal lineages and enhanced expression
of SOX2, NANOG, KLF4, and/or OCT4 transcription factors, but not enhanced self-renewal or tumorigenicity when compared
to their adherent counterparts. Gene expression profiling attributed a neural crest cell signature to these spheroids and
indicated that a migratory/invasive and immune-function modulating program could be associated with these cells. In vitro
assays confirmed that spheroids display enhanced migratory/invasive capacities. In immune activation assays, spheroid cells
elicited a poorer allogenic response from immune cells and inhibited mitogen-dependent T cells activation and proliferation
more efficiently than their adherent counterparts. Our findings reveal a novel immune-modulator function of melanoma
spheroids and suggest specific roles for spheroids in invasion and in evasion of antitumor immunity.
Conclusion/Significance: The association of a more plastic, invasive and evasive, thus a more aggressive tumor phenotype
with melanoma spheroids reveals a previously unrecognized aspect of tumor cells expanded as spheroid cultures. While of
limited efficiency for melanoma initiating cell identification, our melanoma spheroid model predicted aggressive phenotype
and suggested that aggressiveness and heterogeneity of melanoma tumors can be supported by subpopulations other
than cancer stem cells. Therefore, it could be constructive to investigate melanoma aggressiveness, relevant to patients and
clinical transferability.
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Introduction
Melanoma represents one of the most aggressive malignancies
with a high tendency to invade secondary sites. Less than 10% of
patients presenting metastasis survive over one year due to the lack
of efficient therapy. Numerous novel therapeutic protocols have
been developed but, display little improvement over existing
chemotherapy protocols. Melanoma presents a variety of pheno-
typic and behavioral features. Melanoma tissues have various
morphologies and immunohistochemical staining of melanoma
lesions for specific markers often leads to heterogeneous results
[1,2,3]. Therefore, one explanation for the therapeutic failures
might reside in the selective targeting of melanoma cells due to
their heterogeneity.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18784The heterogeneity is illustrated by the existence of multi
subpopulations within a melanoma tumor. Several gene expres-
sion studies suggested that there are specific transcriptional
signatures that delineate melanoma cells subpopulations [4,5,6].
Importantly, in vivo studies showed that these specific transcrip-
tional signatures are linked and reversible given appropriate
signals and microenvironment cues, which suggested that
melanoma progression is associated with transcription signature
plasticity [7]. These studies thus, provide a rational context for
melanoma cells heterogeneity. One noteworthy example of
melanoma cell plasticity is the ability of aggressive melanoma
cells to adopt endothelial-like properties and mimic embryonic
vasculogenic networks [8]. Another example is the observation
that placing metastatic melanoma cells in a chick embryo
microenvironment or in zebra fish embryos suppresses their
tumorigenic phenotype and reprograms the metastatic phenotype
of a subpopulation of tumor cells [9,10]. The tumorigenic
phenotype of aggressive melanoma cells is also suppressed when
placed in human embryonic stem cell microenvironment [11].
Interestingly, growing melanoma cells from metastatic or
primary lesions as spheroids in human embryonic or neural stem
cells medium further supported the notion of plasticity by defining
subpopulations capable of self-renewal and differentiation into
multiple lineages [12,13,14]. These spheroid cells displayed
enhanced tumorigenicity and were enriched with melanoma
initiating or melanoma cancer stem cells (CSC) [12,13,14].
Growth of tumor cells in three-dimensional multicellular tumor
spheroid cultures has been considered to replicate some of the
complex features of in situ solid tumors. Indeed, tumor spheroid
cultures are a rather classical approach to obtain and maintain the
functional phenotype of human tumors, and thus represent a more
physiologically relevant in vitro model of tumors. Yet the utility of
sphere-formation under stem cell conditions as a surrogate tool for
CSC identification in human melanoma has been recently
challenged given the lack of clear and consistent correlations
between melanoma initiating or CSC phenotype with sphere-
forming ability [15]. However, sphere-formation of murine
melanoma cells on non-adhesive substrates such as polyHema
was suggested as an appropriate model to mimic the different
growth and progression patterns obtained in vivo [16,17,18]. In
addition, the gene expression profile of human melanoma
spheroids formed under the same conditions was shown to be
profoundly affected and marked by upregulation of a number of
genes recognized to play a role in melanoma progression [19].
However, it remains unclear whether sphere-formation of human
melanoma cells under stem cell conditions, which is often
associated with high plasticity, can predict molecular or functional
phenotypes associated with aggressiveness. Insights into this
possibility could demonstrate the relevance of such a model for
patients and clinical transferability.
In this study we evaluated the capacity of human melanoma
spheroids formed under stem cell conditions to predict an
aggressive phenotype. Melanoma tumor cells are derived from
the transformation and proliferation of melanocytes, which arise
from the embryonic neural crest. Therefore, we analyzed the
molecular and functional phenotypes of melanoma spheroids
grown in neural crest cells medium in comparison to their
adherent counterparts. Whether derived from metastatic or
advanced primary melanoma specimens, these spheroids ex-
pressed melanoma-associated markers, displayed high capacity to
differentiate along mesenchymal lineages, and showed enhanced
expression of the human embryonic stem cells pluripotency
markers SOX2, NANOG, KLF4, and/or OCT4, which indicates
a higher plasticity. These spheroid cells did not possess the
fundamental properties of melanoma initiating cells; they did not
show enhanced self-renewal or enhanced tumor formation
capacity when compared to their adherent counterparts suggesting
that they were not enriched with melanoma initiating cells.
However, comparative global gene expression and functional in
vitro assays indicated that these melanoma spheroid cells exhibit a
neural crest cell signature associated with enhanced migratory/
invasive and immune evasion capacities, two functions involved in
tumor aggressiveness. Thus, human melanoma spheroids in our
model showed a more aggressive tumor phenotype and suggested
that aggressiveness and heterogeneity of melanoma tumors can be
supported by subpopulations other than cancer stem cells.
Therefore, they could be suggested as a constructive model to
investigate melanoma aggressiveness.
Materials and Methods
Cell culture
Melanoma cells were obtained from a lymph node metastasis
(SLM8) and from a biopsy of a primary stage IV-cutaneous
melanoma (Mela1). Patients signed an informed consent following
human ethics committee (Comite ´ consultatif pour la protection des
personnes dans les recherches biome ´dicales, Ho ˆpital Saint Louis,
Paris, France), and the study has been approved by the institution.
Single-cell suspensions were generated by enzymatic digestion of
the biopsy in 2 mg/mL Collagenase (Sigma-Aldrich, Saint-
Quentin Fallavier, France) in DMEM/F12 medium (Invitrogen,
Cergy Pontoise, France) for 2 h at 37uC. SLM8 and Mela1 cells
were grown as monolayer adherent cells in DMEM/F12
supplemented with Penicillin-streptomycin (100 U/mL and
100 mg/mL, Invitrogen), L-Glutamine (2 mM, Invitrogen), and
fetal calf serum (FCS, 10%, Invitrogen). Between passages 6 and
12, adherent cultures homogeneously express melanoma markers
(HMB-45-reactive antigen, MART1/Melan A, tyrosinase), ensur-
ing their purity from non-tumor contaminating cells. Melanoma
multicellular spheroids were generated by culturing these adherent
cells after dissociation at a clonal density of 1000 cells/mL in
neural crest cells culture conditions, where FCS is replaced by B27
(16, Invitrogen), EGF (20 ng/mL, Upstate, Millipore, Guyan-
court, France), bFGF (20 ng/mL, Invitrogen) and LIF (10 ng/mL,
Chemicon International, Millipore) as described [20]. Experi-
ments were performed with individual cells derived from spheroids
formed after 11 to 21 days. Spheroids were dissociated as
previously described [12]. The expression of frequently tested
melanoma markers (HMB-45-reactive antigen, MART1/Melan
A, tyrosinase) was verified on adherent cells and on single-cell
suspensions from spheroids using anti-pan melanoma
(HMB45+M2-7C10+M2-9E3+T311) antibodies cocktail (Novus
Biological Inc, Littelton, CO, USA).
In vitro limited dilution assays
In vitro self-renewal assessment was performed as described [21].
Briefly, dissociated cells from melanoma adherent and spheroid
cultures were serially diluted in appropriate medium and seeded at
1 cell/well. Wells containing spheroids formed from one cell and
wells containing one colony of adherent cells were counted after
one, two and three weeks.
Flow Cytometry
Expression of markers was determined by immunostaining as
described [22] using: FITC-conjugated anti-avb3 (23C6), PerCP-
conjugated anti-CD20 (L27), anti-CD146(MCAM) (P1H12), anti-
CD80 (L307.4), anti-CD86 (FUN-1) from BD Biosciences (Le Pont
de Claix, France); PE-conjugated anti-CD133/2 (293C3) from
Melanoma Spheroids Aggressiveness
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(5D3) from (Chemicon International, Millipore); anti-CD166
(L50), anti-nestin (3 k1) from Abcam (Paris, France); anti-MHC
I (W6:32), anti-MHC II HLA-DR (L243), HLA-DP (B7/21),
HLA-DQ (33.1), anti-CD40 (G28.5) were affinity-purified from
ascites using protein A-Sepharose column (Amersham Pharmacia
Biotech). Un-conjugated primary antibodies were detected with
PE-conjugated goat anti-mouse IgG(H+L) antibody (BD Biosci-
ences). Cells were analyzed using a FACScan flow cytometer (BD
Biosciences).
Immunohistochemistry
Melanoma adherent cells or melanoma spheroid cells were
cytocentrifuged onto slides (cytospin). After fixation/permeabilisa-
tion with methanol/acetone for 10 min, slides were incubated with
anti-pan melanoma (HMB45+M2-7C10+M2-9E3+T311) for
15 min, then with streptavidin alkaline phosphatase for another
15 min. Alkaline phophatase activity was developed using Fuchsin
plus Substrate-Chromogen System (DAKOCytomation, Trappes,
France) for 10 min.
Differentiation assays of melanoma cells
Melanoma cells were assessed for their capacity to differentiate
along adipogenic and osteogenic lineages. For adipogenic lineage,
single-cell suspensions from adherent and spheroid cultures of
SLM8 and Mela1 were plated in tissue culture-grade plastic at a
density of 50610
3 cells/cm
2 and allowed to differentiate in
adipogenic culture medium (PromoCell, Belgium) for two weeks as
recommended by the manufacturer. After differentiation, accu-
mulation of lipid vacuoles was visualized by staining with Oil Red
O (Sigma-Aldrich). For osteogenic lineage, single-cell suspensions
were plated at 3610
3 cells/cm
2 in osteogenic culture medium
(PromoCell) for two-three weeks as recommended by the
manufacturer. After differentiation, activity of Alkaline Phospha-
tase was assessed using Alkaline Phosphatase activity detection kit
(Sigma-Aldrich) according to the manufacturer’s recommenda-
tions. Oil Red O-stained cells and cells presenting alkaline
phosphatase activity were counted under a light microscope.
Assays were performed in triplicates.
Western Blot analysis
OCT4, NANOG and SOX2 expression was analyzed in total
cell extracts (50 mg) separated by 10% SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose transfer mem-
brane (GE Healthcare Life Sciences, France). The membranes
were washed in Tris-buffered saline with Tween (10 mM Tris-
HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20), blocked 1 h at
room temperature with 5% nonfat milk or 1% BSA in Tris-
buffered saline with Tween, then probed 1 h at room temperature
with anti-OCT4 (Abcam,), anti-NANOG (Abcam), and anti-
SOX2 (Santa Cruz Biotechnologies, Germany). After incubation
with horseradish peroxide-conjugated secondary antibody, immu-
noreactive proteins were detected by ECL detection system (GE
Healthcare). Protein concentrations were determined by using the
BCA protein assay kit (ThermoScientific Biosciences, France).
Migration and invasion assays
Migration and invasion assays were performed in 24-well plates
transwell chambers with 8 mm-pore polycarbonate filter inserts
(BD Biosciences). 5610
4 dissociated spheroid or adherent cells
were seeded on uncoated inserts whereas 10
5 cells were seeded on
collagen type I - or Matrigel-coated inserts in 100 mL of serum-free
medium. The lower chambers were filled with 0.5 ml of 10%
FCS-supplemented DMEM/F12 medium. After 24 h and/or
48 h, cells on the upper side of the filter were removed and the
cells on the lower surface of the insert were fixed and stained with
Diff-Quik staining Kit (Medion Diagnostics; Du ¨dingen, Switzer-
land). The number of stained cells was counted under a light
microscope. Assays were performed in triplicates.
Immunogenicity assays
Peripheral blood mononuclear cells (PBMCs) were prepared by
centrifugation on a Ficoll-Hypaque density gradient (Sigma-
Aldrich) of blood samples from healthy donors characterized for
their MHC haplotype. The haplotypes of SLM8 and Mela1
melanoma cells were HLA-DRB1*07/11, HLA-DQB1*02/03,
and HLA-DRB1*13/07,HLA-DQB1*06/02, respectively. To
determine the capacity of melanoma cells to elicit an allogeneic
response, 1610
5 responding PBMCs were co-cultured with either
allogeneic stimulatory PBMCs (1610
5 cells) or dissociated
melanoma spheroid cells or melanoma adherent cells (1610
4
cells) treated with mitomycin C (20 and 50 mg/mL, respectively,
for 30 min) in U-bottom 96-wells plates. PBMCs proliferation was
determined by
3H-thymidine pulse (1 mCi/well) for 18 h prior to
the end of experiment. In assays determining melanoma
suppressive effect, dissociated spheroid cells or melanoma
adherent cells treated with mitomycin C (50 mg/mL) were co-
cultured with HLA-matched PBMCs labeled with CFSE (1 mM
for 10 min) in the presence of phytohemagglutinin (PHA). At the
indicated time point, cells were stained with eFluor780-conjugated
anti-CD3 (UCHT1, eBiosciences), PE-conjugated anti-CD25 and
7AAD (BD Biosciences) to determine T cell activation, prolifer-
ation and death. Cells were then analyzed by Canto II flow
cytometer (BD Biosciences).
RNA Isolation and Reverse Transcription–PCR
Total RNA extraction, the conditions of reverse transcription,
and the quantitative PCR (Q-PCR) and semi-quantitative PCR
(sq-PCR) analysis were carried out as we described in [22]. For Q-
PCR, specificity of PCR amplicons was confirmed by melting
curve analysis and relative expression of tested genes was
calculated using the target threshold (CT) value and the 2
2DDCt
method [23]. For each gene, values were averaged over three
independent measurements and relative transcript level was
calculated. For sq-PCR, the number of cycles was evaluated for
each primer set and experiment as maintaining an exponential
amplification. For both Q- and sq-PCR, RPL13 was used as the
housekeeping gene, and the nucleotide sequences of the different
primers along with the corresponding annealing temperature and
number of cycles performed are indicated in tables S10 and S11
(supplementary information).
Affymetrix Exon Array hybridization
One mg of total RNA from SLM8 and Mela1 adherent and
spheroid cells were extracted using Trizol (Sigma-Aldrich) then
labeled with reagents from Affymetrix. Hybridization cocktails
containing 5–5.5 mg of fragmented, end-labeled single-stranded
cDNA were prepared and hybridized to Affymetrix-GeneChipH
Human Exon 1.0 ST arrays (Affymetrix). Processed arrays were
scanned using the GeneChip Scanner 3000 7G. Affymetrix
Expression Console Software was used to perform quality
assessment.
Data analysis. Data were processed by the EASANAH
analysis system and visualization interface (GenoSplice
technology, Paris, France), which is based on the FAST DB
annotations [24]. Array data were normalized using quantile
normalization method and corrected using the antigenomic probes
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[26,27,28,29]. Only probes targeting exons annotated from full-
length cDNA were kept for analysis. Among these pre-selected
probes, bad quality probes and probes with intensity signal too low
compared to antigenomic background probes with the same GC
content were disregarded. Only probes with a DABG p-
value#0.05 in at least half of chips were considered for further
statistical analysis as described [26,27,28,29]. The experiment
(from cell injection to array hybridization) was performed three
times. Paired statistical analyses were performed using Student’s
paired t-test on the gene signal intensities (gene level) as described
[26,27,28,29]. Results were considered statistically significant at p-
values#0.05 and fold-change $1.5. Hierarchical clustering was
carried out to cluster among the gene signal intensities and among
the samples with Mev4.0 software from TIGR (The Institute of
Genome Research). Euclidean distance with complete linkage was
used. The functional analyses were generated through PANTHER
[30].
Statistical analysis
Results are presented as mean values 6 SD of at least three
independent experiments. Statistical differences between samples
were determined using OneWay ANOVA followed by Student-
Newman-Keuls method (SigmaStat software) and a p-value of
,0.05 was considered significant.
Results
Melanoma cells expanded as spheroid cultures in neural
crest cell medium show high plasticity and enhanced
expression of human embryonic stem cells pluripotency
transcription factors
Whether from a lymph node metastasis (SLM8) or from a
primary stage IV-cutaneous lesion (Mela1), melanoma cells when
seeded at a clonal density in neural crest cells medium form small
floating spheroid structures (15–30 cells) within 2 days of culture
that grow to approximately 200 cells each within 2 weeks (Fig. 1A).
Similar to their adherent counterparts, both Mela1 (Fig. 1B) and
SLM8 (data not shown) spheroid cells stain positively for at least
one of the frequently tested melanoma markers HMB-45,
MART1/Melan A and/or tyrosinase (Fig. 1B). Spheroid cells
derived from SLM8 expressed melanoma-associated markers
integrin avb3 [31] and CD146 (M-CAM) [32], the neuroectoder-
mal stem cells marker nestin [33,34], and the mesenchymal stem
cells surface molecule CD166 [34,35] (Fig. 1C). Mela1 spheroid
cells also expressed CD146, CD166, nestin, but not integrin avb3
(Fig. 1C), which could be due to the tumor progression state of
Mela1 cells given that avb3 is reported as mainly expressed in
metastatic regions [31]. Spheroids showed an expression profile
similar to their adherent counterparts, albeit for decreased
expression of melanoma-associated marker CD146 (Fig. 1C).
Given the neuroectodermal origin of melanocytes, we evaluated
the capacity of these spheroid cells to differentiate along the
mesenchymal lineages. We compared the extent of adipogenic and
osteogenic differentiation of SLM8 and Mela1 spheroid cells versus
their adherent counterparts. Under conditions sustaining adipo-
genic differentiation, both spheroids and adherent cells from
Mela1 (Fig. 2A left panel) and SLM8 (Fig S1 A, Supplementary
data) presented Oil Red O-stained lipid vacuoles. Twenty-four
65.17% and 16.265.4% of SLM8 and Mela1 adherent cells,
respectively, were Oil Red O-positive compared to 44.967.3%
and 37.668.6% of SLM8 and Mela1 spheroids, respectively
(Fig. 2A right panel). SLM8 (Fig. 2B left panel) and Mela1 (Fig S1
B, supplementary data) spheroid cells and their adherent
counterparts were also able to differentiate along osteogenic
lineage in osteogenic medium. Nearly 25.464.7% and 31.561.0%
of SLM8 and Mela1 spheroids and 11.963.4% and 17.462.3 of
their adherent counterparts, respectively, presented alkaline
phosphatase activity (Fig. 2B right panel). These results show
higher capacity of spheroid cells to differentiate along mesenchy-
mal lineages and suggest that melanoma spheroids grown under
neural crest cell conditions are enriched with multipotent cells
when compared to their adherent counterparts.
As OCT4, NANOG, SOX2, and KLF4 are recognized as
regulators of cells pluripotency and as human embryonic stem cells
markers [36,37,38,39], we investigated the expression of these
transcription factors in our model. Quantitative PCR analysis
showed that spheroid cells from SLM8 and Mela1 express
significantly higher levels of NANOG, SOX2 and KLF4
compared to their adherent counterparts (Fig. 3A). Spheroid cells
from SLM8, but not from Mela1, also showed enhanced
expression of OCT4 (Fig. 3A). Western blot analysis also showed
that SLM8 spheroid cells express enhanced levels of OCT4,
NANOG and SOX2 over their adherent counterparts (Fig. 3B).
Compared to their adherent counterparts, Mela1 spheroid cells
displayed higher levels of SOX2 and NANOG, but not OCT4
(Fig. 3B). These results show that melanoma spheroid cells grown
under neural crest cell conditions display high plasticity as they are
enriched with multipotent cells and express higher levels of
pluripotency regulators. This supports the notion that these
melanoma spheroids could be enriched with cells possessing stem
cell-like properties.
Melanoma spheroid cells do not display the properties of
melanoma stem cell-like or initiating cells
We then investigated if spheroids are enriched with melanoma
stem cell-like or initiating cells. We first examined the expression of
putative markers of these cells CD20, CD133, ABCG2 and
ABCB5 [12,13,40]. Flow cytometry showed that melanoma
spheroid cells whether derived from SLM8 or from Mela1 were
negative for CD133, CD20 and ABCG2 (Fig. 4A). Indeed,
melanoma spheroid cells displayed the same expression pattern as
their adherent counterparts with the exception of ABCG2, which
was expressed by 63.6% of SLM8 adherent cells. The expression
of ABCB5 was not detectable by immunostaining, western blot, or
flow cytometry analysis in either spheroid or adherent cells from
SLM8 and Mela1 melanoma (Fig S3, Supplementary data). The
expression of ABCG2 or ABCB5 is often associated with cells
having the property of side-population cells [13], which usually
presents cells having drug-efflux activity [41,42]. Therefore, we
conducted drug efflux experiments and found that neither
adherent nor spheroid cells from both SLM8 and Mela1 have
the property of side-population cells (Fig S2, Supplementary data)
thus, supporting the above results. The melanoma stem cell-like or
initiating cells marker expression does not seem to be related to
culture duration given that phenotype analysis at different time
points during culture yielded similar results (data not shown).
We then investigated through limited dilution assays the self-
renewal potential of melanoma spheroid cells in comparison with
their adherent counterparts. SLM8 and Mela1 spheroids were
dissociated and plated into 96 wells as a single cell per well, and
the number of wells containing a single cell able to generate
spheroid structures was determined. Single cells derived from
SLM8 and Mela1 spheroids generated spheroids at 60–70% and
8–9%, respectively (Fig. 4B), showing the potential of these clonal
tumor spheroids to generate colonies although with different
efficiency. Interestingly, adherent SLM8 and Mela1 cells demon-
strated clonal efficiency similar to their respective spheroid
Melanoma Spheroids Aggressiveness
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indicate that spheroid cells in our model do not show enhanced
self-renewal when compared to their adherent counterparts.
Furthermore, these melanoma spheroid cells displayed the same
capacity of tumor formation as their adherent counterparts when
serially xenotransplanted into nude mice (Fig S4, Supplementary
data). Together these results indicate that spheroids are highly
plastic cells but are not enriched with melanoma stem cell-like or
initiating cells given that they do not present enhanced
tumorigenic and self-renewal capacities when compared with
their adherent counterparts.
Gene expression profile of melanoma spheroid cells
versus their adherent counterparts
To determine whether melanoma spheroids in our model could
predict a molecular or functional phenotype, we performed gene
expression profiling experiments using Affymetrix microarrays.
The data have been deposited in NCBI’s Gene Expression
Figure 2. Melanoma spheroid cells display higher capacity to differentiate along mesenchymal lineages. A. Adipogenic differentiation
of melanoma adherent (MA) cells and spheroid (MS) cells was assessed by Oil Red O staining. Left panel shows Mela1 undifferentiated and
differentiated MA and MS cells (magnification6100). Right panel demonstrate the extent of adipogenic differentiation of Mela1 and SLM8 melanoma
cells as percentage of Oil Red O stained cells. B. Osteogenic differentiation of MA and MS cells was assessed by alkaline phosphatase (AP) activity
detection. Left panel shows SLM8 undifferentiated and differentiated MA and MS cells (magnification610). Right panel presents the percentages of
cells presenting AP activity. Results are mean percentage values of cell counts obtained in 15 independent microscope fields 6 SD, *p,0.001.
doi:10.1371/journal.pone.0018784.g002
Figure 1. Melanoma spheroid cells grown under neural crest cells conditions and their adherent counterparts have common
phenotypes. A. SLM8 and Mela1 monolayer adherent melanoma cells (SLM8-MA and Mela1-MA) form multicellular spheroids (SLM8-MS and Mela1-
MS) under neural crest cell conditions (magnification 650 for MA cells; 620 and 650 for MS cells). B. Mela1-MS, similarly to Mela1-MA, cells express
melanoma markers, as determined by immunostaining with anti-pan melanoma antibodies (HMB45+M2-7C10+M2-9E3+T311) and Mayer’s
hematoxylin counterstaining. C. Expression of avb3, CD146, CD166 and nestin was determined by flow cytometry (grey filled histogram versus
unfilled histograms for respective isotype control).
doi:10.1371/journal.pone.0018784.g001
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number GSE26980 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE26980).
Global probing for differences in gene expression in spheroid cells
compared to their adherent counterparts showed statistically
significant altered expression of 273 (up) and 189 (down) genes for
SLM8, and 185 (up) and 205 (down) genes for Mela1 in the
microarray using a paired t-test with p-values#0.05, fold-change
$1.5 and excluding non-annotated genes (Fig S5, Supplementary
data). Heatmaps were established with the 100 more regulated genes
for both SLM8 and Mela1 cells (Fig. 5). Changes in gene expression
were found to be common but also distinct for each cell line: among
all the regulated genes, 58 genes were found to be commonly up-
regulated in Mela1 and SLM8 spheroid cells and 7 to be commonly
down-regulated (Fig S5 and Table S1, Supplementary data).
RT-PCR was employed to confirm the differential expression of
10 representative genes, which were chosen based on their
implication in neural crest cells function, particularly adhesion
and motility, in tumor progression and/or regulation of immune
response. A good correlation between microarray and RT-PCR
data was observed for most of the validated genes (Fig. 6). SLM8
andMela1spheroidcellsexpressedenhancedlevelsofGDF11while
showing decreased expression of GDF15; both genes belonging to
the BMP/GDF group of the TGFb superfamily and being
regulators of cell growth and differentiation in embryonic and
adult tissues and in tumors progression [43]. Both spheres
populations also over-expressed JAG1 (Jagged 1), a ligand of Notch
receptor that is involved in developmental processes as well as in the
development of regulatory T cells in both human and mouse
systems [44,45,46]. Even though at different levels, Mela1 and
SLM8spheroid cells also showed upregulated expression of IL-16, a
pleiotropic cytokine that is a natural ligand of CD4 and is a chemo-
attractant for CD4
+ T cells, particularly T regulatory cells [47], and
SNAI2 (Slug), a master regulator of neural crest cell specification
and migration and is implicated in melanoma progression [48,49]
(Fig. 6A). Mela1 spheroid cells over-expressed EphA3, Sema5a and
ErbB4 (Fig. 6B) whereas SLM8 spheroid cells over-expressed
EphA2 and Sema3D (Fig. 6C). While not always identical, these
over-expressed genes by melanoma spheroid cells grown under
neural crest cells conditions do belong to the same families and/or
participate in similar processes such as embryonic neural crest cell
migration and cell fate regulation [43,48], tumor progression [50],
and growing evidence also indicates their involvement in regulation
of immune response [51,52].
Melanoma spheroid cells transcription signature puts
them forward as highly plastic cells that could assume
the role of aggressive melanoma cells
Using the Panther software, we then defined the biological
processes, molecular functions and signaling pathways involving
Figure 3. Melanoma spheroid cells display higher expression of pluripotency transcription factors. A. Expression of pluripotency
transcription factors OCT4, NANOG, SOX2 and KLF4 by spheroid (MS) and adherent (MA) cells from SLM8 and Mela1 was determined by quantitative
PCR. Results are presented as mean values of relative mRNA expression 6 SD from three independent experiments; *p,0.05; **p,0.005. B. Western
blots with specific antibodies demonstrating the up-regulation of OCT4, NANOG and SOX2 expression in MS cells compared to MA. Re-blotting with
anti-beta-actin ensured equal loading.
doi:10.1371/journal.pone.0018784.g003
Melanoma Spheroids Aggressiveness
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18784the regulated genes in spheroid cells compared to adherent cells
(Fig. 7). The biological processes profiling revealed that for both
SLM8 and Mela1 cells, the highest number of regulated genes in
spheroid cells concerned developmental processes (Fig. 7 and
Table S2, supplementary data), which encompass ectoderm,
mesoderm and skeletal development, and neurogenesis (Fig. 7
and Table S3, supplementary data). This suggests gene
expression changes in melanoma spheroids in agreement with
their higher expression of pluripotency regulators and differen-
tiation capacity. Besides, various genes involved in cell structure,
motility, and adhesion, as well as extra-cellular matrix protein-
mediated and cell adhesion signaling were differentially expressed
(Fig. 7 and Table S4 and S5 supplementary data) and were
suggestive of an enhanced capacity of the spheroid cells to
migrate. Interestingly, both Mela1 and SLM8 spheroid cells
also regulated several genes involved in immunity and defense
and/or immune-related processes (Fig. 7 and Table S6
supplementary data).
Figure 4. Melanoma spheroids are not enriched with putative melanoma CSCs. A. Expression of CD133, CD20 and ABCG2 by SLM8- and
Mela1-MA and -MS cells determined by flow cytometry (grey filled histogram versus unfilled histograms for respective isotype control). B. Cloning
efficiency of spheroid (MS) and adherent (MA) cells from SLM8 and Mela1 as determined by limiting dilution assays over three weeks. Results are
expressed as mean percentage values 6 SD from 4 different experiments.
doi:10.1371/journal.pone.0018784.g004
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18784In agreement, the molecular profiling revealed in spheroid cells
a high number of regulated genes encoding for cytoskeleton, extra-
cellular matrix, cell adhesion, immune response-related receptors
and membrane bound signaling proteins (Fig. 7 and Table S7 and
S8, supplementary data). Finally, the pathway profiling revealed
that genes implicated in Notch, Endothelin, angiogenesis as well as
axon guidance pathways are also differentially regulated in
spheroid cells (Fig. 7 and Table S9 supplementary data), which
could be either directly or indirectly linked to the above
underscored biological processes. Besides concurring with higher
plasticity, the global functional analysis of melanoma spheroid cells
transcriptional profile also suggested that a migratory/invasive
and/or immune-function modulating program could be associated
with these melanoma spheroid cells.
Melanoma spheroid cells display higher in vitro
migratory/invasive capacity
To corroborate the obtained melanoma spheroid cells
transcriptional profile we conducted in vitro assays to evaluate
the migratory/invasive capacity of melanoma spheroid cells in
comparison with their adherent counterparts. Using Transwell
migration chambers, we found that spheres grown under neural
crest cells conditions display a significant increase in cell motility.
Compared to SLM8 adherent cells, SLM8 dissociated spheroid
cells showed a 3.6-fold (p,0.05) and 3-fold (p,0.005) increase in
chemotactic potential at 24 and 48 h, respectively (Fig. 8A).
These cells also demonstrated higher capacity to invade both
Matrigel- and collagen I-coated inserts in Transwell migration
chambers. Significantly higher numbers of SLM8 spheroid cells
were able to invade Matrigel and collagen I as compared to
SLM8-adherent cells (p,0.05 and p,0.005, respectively)
(Fig. 8B). Similar results were also obtained when spheroid and
adherent cells from Mela1 were compared for their migration
and invasion capacities (data not shown). These results indicate
that melanoma spheroid cells, compared to their adherent
counterparts are endowed with higher migratory/invasive
capacity attributing to spheroid growth pattern a functional
phenotype associated with tumor aggressiveness.
Melanoma spheroid cells are more efficient in
modulating the immune response
We then tested whether an immune-function modulating
program could be associated with the melanoma spheroid cells.
First, we evaluated the expression of immunologically relevant cell
surface molecules by SLM8 and Mela1 dissociated spheroid and
adherent cells (Fig. 9A and 9B). SLM8 adherent cells were positive
for MHC class I, MHC class II (HLA-DR, DQ, and DP), CD40
but very weakly positive for co-stimulatory molecules CD80 (B7.1)
and CD86 (B7.2). Mela1 adherent cells were similarly positive for
MHC class I, CD40, expressed lower levels of MHC class II
(HLA-DR, DQ, and DP), and were negative for CD80 and weakly
positive for CD86. SLM8 and Mela1 spheroid cells displayed
comparable immunological phenotypes to their adherent coun-
terparts although with a decrease in the expression of MHC class
II molecules.
The allogeneic mixed lymphocyte reaction (MLR), where
lymphocytes from MHC incompatible individuals will stimulate
each other to proliferate significantly, has served as an important
experimental system for elucidating the cellular and molecular
basis of human lymphocyte responses. The one-way MLR test
where the lymphocytes from one of the individuals are inactivated
by mitomycin C or irradiation, thereby allowing only the
untreated remaining population of cells to proliferate in response
to foreign MHC antigens, has been adapted for elucidating the
immunological properties of various cells including mesenchymal
stem cells [53]. Therefore, to provide insights into the immuno-
logical properties of melanoma spheroid cells, we sought to
investigate their capacity to elicit an allogenic response in a one-
way MLR. Un-fractionated allogeneic peripheral blood mononu-
clear cells (PBMCs) were co-cultured with mitomycin-treated cells
from melanoma spheroids or adherent cultures in 96 wells for 6
days. Un-fractionated PBMCs responded vigorously to mitomy-
cin-treated allogenic PBMCs (Fig. 10). The proliferative response
to SLM8 and Mela1 adherent cells from the same donor was 60%
and 66% lower, respectively, whereas that of SLM8 and Mela1
spheroid cells was 77% and 79% lower, respectively (Fig. 10A and
10B). Co-culturing with higher titers of melanoma cells did not
enhance the immunogenicity of either spheroid or adherent cells
(data not shown). To exclude apoptotic cell death as a potential
cause of less efficient proliferation, we quantified cell death at days
2 and 4 of the allogenic co-cultures by 7-AAD staining and flow
cytometry. We found that neither melanoma adherent nor
spheroid cells from both SLM8 and Mela1 induced cell death in
PBMCs above baseline levels. Although SLM8 cells express higher
levels of MHC class II molecules than Mela1 cells, both cell lines
elicited a comparable allogeneic response, which is probably due
Figure 6. Differential expression of representative genes. RT-
PCR of representative genes was performed with mRNA extracted from
SLM8- and Mela1-spheroid (MS) and -adherent (MA) cells, using specific
primers as indicated in Table S10 (supplementary data). RPL13 is used
as housekeeping gene to ensure equal loading.
doi:10.1371/journal.pone.0018784.g006
Figure 5. Global gene expression profiling. Affymetrix microarray was performed with mRNA extracted from SLM8- and Mela1-spheroid (MS)
and -adherent (MA) cells. Heatmaps of the 100 more regulated genes for SLM8 and Mela1 cells.
doi:10.1371/journal.pone.0018784.g005
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and which are different between SLM8 and Mela1. These results
indicate that although both melanoma cell populations have poor
stimulatory function, melanoma spheroid cells are significantly less
efficient than their adherent counterparts in eliciting an allogeneic
response.
Figure 7. Global functional analysis of modulated genes. PANTHER software was used to determine the regulated biological processes (upper
panel), the molecular functions (middle panel), and the signaling pathways (lower panel). Bars represent the number of regulated genes.
doi:10.1371/journal.pone.0018784.g007
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and adherent cells on mitogen-activated T cell proliferation.
PBMCs from healthy donors (n=3) having an MHC haplotype
compatible with SLM8 (SLM8-matched) were labeled with CFSE
and then activated with phytohemagglutinin (PHA) in the
presence or absence of SLM8 adherent or spheroid cells for 4
days. T cell proliferation was then assessed by FACS analysis of T-
cell CFSE labeling. As shown in figure 11A, the presence of SLM8
adherent cells decreased the PHA-induced T cells proliferation
only by 8.5% whereas the presence of SLM8 spheroid cells
induced a reduction of 43%. Analysis of cell death and expression
of CD25 as a marker of T cell activation showed that in the
presence of SLM8 spheroid cells, but not adherent cells, T cell
death increased from 23% (baseline) to 34.5% while the
percentage of CD3
+CD25
+ cells decreased from 60.5% (baseline)
to 36.6% (Fig. 11B). These results suggest that although adherent
melanoma cells are able to inhibit T cell proliferation, melanoma
spheroid cells are endowed with higher capacity to inhibit both T
cells activation and proliferation. Together our findings attribute a
novel immune-modulator function to highly plastic melanoma
spheroid cells and suggest specific roles for these spheroids in the
evasion of antitumor immunity.
Discussion
Melanoma tumors are recognized for their heterogeneity and
plasticity, which challenges the development of efficient therapies.
In this study we showed that melanoma cells expanded as spheroid
cultures under neural crest cells conditions have a neural crest cells
transcriptional signature associated with high transdifferentiation
capacity. Importantly, these spheroids are endowed with enhanced
migration/invasion capacities and more efficient immune-modu-
lator function, but are not prominently enriched with melanoma
stem cell-like or initiating cells. Our study reveals a previously
unrecognized aspect of tumor cells expanded as spheroid cultures
by attributing a novel immune-modulator function to more plastic
and invasive cells. Thus, melanoma spheroid growth in our
conditions predicted a more aggressive tumor phenotype while
corroborating its limited efficiency to enrich or identify cancer
stem or tumor initiating melanoma cells.
It has been proposed that the aggressiveness and heterogeneity
of tumors is supported by rare cell subpopulations within tumor;
the cancer stem cells (CSCs), also known as tumor initiating cells.
The notion of CSCs and the definition of CSC populations are not
yet fully clear in melanoma [54,55,56]. Although debated, the
CSC notion has been supported by several studies showing
prospective purification of melanoma cell subpopulations that
express different markers and possess the fundamental CSC
properties of enhanced self-renewal, differentiation and enhanced
tumorigenic capacity [12,13,40,57,58]. Expanding tumor cells as
spheroid cultures has been used by several groups to enrich and
identify CSCs or tumor initiating cells [12,13,14], but its utility in
identifying melanoma-initiating cells has been recently challenge
[15]. Melanoma spheroids in our model presented higher
transdifferentiation capacity, which is in accord with previous
studies [12,13]. However, in contrast to [12,13,14] our spheroid
cells did not show higher tumorigenic or extensive self-renewal
capacities when compared to their adherent counterparts. This
indicates that both adherent and spheroid cells in our model
contain tumor cell subpopulations with capacity to form tumors
but melanoma spheroids are not prominently enriched with tumor
initiating cells. This is supported by our data showing no increase
in the expression of markers, such as CD20 and CD133,
previously associated with melanoma stem cell-like or initiating
cells, in melanoma spheroids when compared to their adherent
counterparts [12,13]. Our global gene analysis showed that the
melanoma initiating cells marker ABCB5 is downregulated in both
SLM8 and Mela1 spheroids compared to their adherent
counterparts, although we did not detect ABCB5 at the protein
level nor find side-population cells described to be associated with
ABCB5 expression [59] in either population. Our results are in
line with the limited efficiency of sphere-formation assay as a
surrogate tool for enrichment and/or identification of CSCs in
melanoma [15]. In addition, our data suggest that aggressiveness
and heterogeneity of melanoma tumors may be supported by
subpopulations other than CSCs.
Spheroid cells in our model displayed a transcriptional profile
marked by the regulation of genes involved in several develop-
mental processes, increased expression of human embryonic stem
cells pluripotency markers, and enhanced transdifferentiation
capacity. Spheroid cells prominently expressed the pluripotency
factors NANOG, KLF4, SOX2 and OCT4, although differences
in the expression levels were observed between Mela1 and SLM8.
These factors were shown to reprogram terminally differentiated
cells to generate induced-pluripotent cells similar to embryonic
stem cells [36,37,39]. Interestingly, global gene expression analysis
also showed that even though the genes modulated in Mela1 and
Figure 8. Melanoma spheroid cells have enhanced migratory/
invasive capacities. A. Chemotaxis (uncoated inserts) and B. invasion
(matrigel- and collagen I-coated inserts) capacities of SLM8 adherent
(MA) and spheroid (MS) cells were assessed using Transwell migration
chambers. Experiments were performed three times in duplicate and
results are presented as relative values against the number of adherent
cells that have migrated (24 h and 48 h) or invaded at 48 h. Bars: SD,
*p,0.05; **p,0.005.
doi:10.1371/journal.pone.0018784.g008
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PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18784Figure 9. Expression of immunological relevant molecules by melanoma spheroid and adherent cells. Expression of MHC I and MHC II
(HLA-DR, HLA-DQ and HLA-DP) molecules (A) and co-stimulatory CD40, CD80, and CD86 molecules (B) was determined by flow cytometry by SLM8
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PLoS ONE | www.plosone.org 13 April 2011 | Volume 6 | Issue 4 | e18784SLM8 spheroid cells are different, the affected developmental
processes in both spheroid cells are overall similar, in particular
the neural crest cell process. Our results suggest that the spheroids
grown under neural crest cells conditions could represent a cellular
population that is enriched with melanoma cells having enhanced
neural crest cell plasticity; given their transcriptional signature,
their higher expression of pluripotency regulators, and their
enhanced adipogenic and osteogenic differentiation. Melanoma
cells injected in chick’s embryo were shown to reverse and behave
as neural crest cells suggesting, the presence, within the bulk of the
tumor, of melanoma cells that can acquire the capacity to reverse
to neural crest cell state [60]. In our model, melanoma spheroids
express HMB-45-reactive antigen, MART1/Melan A and/or
Tyrosinase melanoma markers. Furthermore, our global gene
analysis also showed the upregulation of the melanocyte-
differentiation gene TYRP1 and master regulator of neural crest
specification SNAI2 (Slug), which is also over- expressed in
aggressive melanoma. Together these findings indicate that
although melanoma spheroids in our model display higher neural
crest cell plasticity, they did not revert to a neural crest stem cell
state and remained melanoma tumorigenic cells.
Our results indicated that melanoma spheroid cells have
enhanced in vitro migration and invasion potential. These
properties characterize aggressive tumor cells but also neural crest
cells. Neural crest cells are an embryonic cell population that gives
rise to cells of multiple fates and are known to migrate extremely
long distance in the embryo [48]. It was strongly suggested that the
high metastatic potential of melanoma cells probably emerges
from the developmental origin of melanocytes in the neural crest
[49]. Our global gene profiling indicated that spheroid cells from
Figure 10. Melanoma spheroid cells elicit lower allogeneic response. Unfractionated PBMCs were cultured in microtiter wells with medium
alone, allogeneic PBMCs, melanoma adherent cells or melanoma spheroid cells from either SLM8 (A) or Mela1 (B). PBMC proliferation was evaluated
at day 6 by
3H-Thymidine incorporation (left panel) and cell death was evaluated at days 2 and 4 by 7-AAD staining and flow cytometry analysis (right
panel). Experiments were performed in quadruplicate and results are presented as mean values 6 SD from 4 independent experiments (*p,0.05;
**p,0.001).
doi:10.1371/journal.pone.0018784.g010
and Mela1 adherent (MA) and spheroid (MS) cells. Unfilled red histograms for spheroids or unfilled black histograms for adherent cells versus grey
filled histograms for respective isotype control. Percentages of positive cells and the mean fluorescence intensity () are indicated.
doi:10.1371/journal.pone.0018784.g009
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cells migration such as SNAI2 (slug), semaphorins, and ephrins.
Furthermore, spheroid cells express high levels of pluripotency
transcription factors. These transcription factors are expressed in
neural crest cells [61], but were also found in invasive tumor cells.
Expression of NANOG and Cripto-1, the co-receptor of NODAL
that acts as mediator of cell fate in embryological and adult
systems, was detected in aggressive melanoma [62]. NANOG [63]
and OCT4 [64] were also found to be expressed in highly invasive
cell populations from other tumors such as prostate cancer and
glioma. It has been proposed that the migratory and invasive
features of aggressive melanoma cells could be supported by cells
that had reactivated elements of the molecular circuitry respon-
sible for the specific migratory behavior of neural crest [49]. The
melanoma spheroids in our model seem to behave along this
theory and therefore, the occurrence of such molecular events
could provide an explanation to the higher migratory and invasive
capacities of these cells.
We have previously analyzed the expression of the immuno-
logical relevant molecules MHC class II on melanoma cells
[22,65], and demonstrated their involvement in melanoma
protection from immune system attacks [66]. Herein, we show
that melanoma spheroid cells demonstrated worse allogeneic
immune stimulatory and enhanced immune-modulator functions
when compared to their adherent counterparts. Given that T cells
are the major fraction of PBMCs proliferating in response to
Figure 11. SLM8 spheroid cells inhibit PHA-induced T cell activation and proliferation. PBMCs from MHC-matched healthy donors (n=3)
stimulated with PHA in the presence or absence of SLM8 spheroid (MS) or their adherent (MA) counterparts. A. Inhibition of T cell proliferation as
determined by FACS analysis of T-cell CFSE labeling as described under material and methods. Percentages of dividing T cells and the mean number
of divisions of the responding cells, proliferation index (PI) are indicated. B. Analysis of T cell death by 7-AAD staining (left panel) and expression of
CD25 as a marker of T cells activation (right panel) by flow cytometry. Experiments were performed in duplicate and results are presented as mean
values 6 SD from 3 independent experiments (*p,0.05; **p,0.001).
doi:10.1371/journal.pone.0018784.g011
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oids in comparison with their adherent counterparts have
decreased capacity to elicit proliferative response from alloreactive
T cells. This possibility is in line with our data showing that
melanoma spheres have enhanced capacity to inhibit proliferation
of MHC-matched mitogen-activated T cells. This inhibition of T
cell proliferation was accompanied with a slight increase in cell
death but more importantly with a significant decrease in the
percentage of cells expressing the activation marker CD25, which
could indicate enhanced immune-modulator function of these
spheroid cells. This could be due to the differential antigen
presentation and/or to the induction of regulatory T cells. Both
melanoma spheroid and adherent cells express MHC class II
molecules, but melanoma spheroid cells showing more pro-
nounced immune-modulator function express slightly lower levels
of these molecules than their adherent counterparts. Melanoma
cells often express various levels of MHC class II molecules, which
have been associated with melanoma progression and poor
prognosis [67,68]. It has been suggested that MHC class II
expression by these tumors might polarize the anti-tumor T cells
response towards regulatory T cells facilitating tumor progression
[69]. A recent study attributed a preferential capacity to modulate
the immune response to melanoma initiating cells expressing
ABCB5 and MHC class II molecules [70]. The authors showed
that ABCB5
+MHC class II
+ cells displayed higher capacity than
ABCB5- MHC class II-negative melanoma cells to inhibit IL-2-
dependent T-cell activation and support the induction of
CD4
+CD25
+FoxP3
+ regulatory T cells. The polarization of T
cell response towards regulatory T cells involves various cell-cell
contact and soluble factor-mediated mechanisms. The polarization
towards regulatory T cells by ABCB5
+ melanoma initiating cells
has been attributed in part to the expression of co-stimulatory
CD86 by these cells [70]. However, both SLM8 and Mela1
spheroids expressed comparable levels of co-stimulatory molecules
including CD86 compared to their adherent counterparts. In
addition, in our model neither ABCB5+ melanoma initiating cells
nor CSCs can support the enhanced immune-modulating capacity
of spheroid cells, given that our spheroids were not prominently
enriched with such cells. Our study thus, reveals a novel immune-
modulator function of melanoma spheroid cells and suggests that
in addition to melanoma initiating cells; other subpopulations
could present enhanced capacity to modulate the immune
response.
Our immune activation assays did not investigate the mecha-
nism(s) through which our melanoma spheroid cells may exert
their enhanced modulator effect(s) on the immune response.
However, our global gene profiling underscored several candi-
dates, which could be involved in the enhanced capacity of
spheroid cells to modulate the immune response. Among these
candidates, we identified IL-16 and Notch ligand Jagged 1, both
over-expressed in SLM8 and Mela1 spheroid cells as potential
targets. It has been shown that IL-16 produced by skin cells can
inhibit alloreactive T cells proliferation inducing local immuno-
suppression prolonging allogeneic skin graft survival [71], and also
contributes to selective regulatory T cells recruitment and
expansion at inflammatory sites [47]. Notch is implicated in T
cell differentiation towards the Th1, Th2, or regulatory T cells in a
ligand-dependent fashion; triggering of Notch with Jagged 1 and
Delta-like1, in contrast to Delta-like4 induces a dose-dependent
inhibition of early activation markers CD69 and CD25 as well as
inhibition of T cell proliferation [45]. The involvement of IL-16
and Jagged 1 in melanoma spheroids enhanced immune-
modulator function would thus, be determined in future studies.
In addition, melanoma spheroids over-express members of the
semaphorin family. Growing evidence indicates that, in addition to
their established role in invasion, semaphorins and their receptors
are implicated in the regulation of immune response and it has
been proposed that semaphorins may help cancer cells to escape
immune surveillance by inhibiting T cell-mediated responses
[51,52]. Thus, semaphorins could also mediate melanoma
spheroids enhanced immune-modulator function.
A recent study of glioma cells suggested that altering the
differentiation state of tumor cells influence their immunosuppres-
sive capacity [72]. The authors showed that transdifferentiation of
glioma-associated cancer-initiating cells along astrocytic, neuronal,
or oligodendroglial lineages decrease their immunesuppressive
capacity. Although not enriched with tumor-initiating cells,
melanoma spheroids also showed high transdifferentiation capac-
ity along adipogenic and osteogenic lineages, and further studies
would address whether their differentiation could impact on their
immunogenic properties.
Tumor cell aggressiveness is often associated with their capacity
to invade and evade immune surveillance. In this context, we
showed that melanoma spheroid cells grown under neural crest
conditions are endowed with important plasticity, which could
indicate high capacity to respond and adapt to various
microenvironmental cues, important capacity to migrate and
invade, which are both essential for tumor metastasis, and
immunomodulator functions suggesting enhanced capacity to
evade immune surveillance. Despite their recognized relevance to
tumor progression and aggressiveness, these enhanced capacities
did not confer to melanoma spheroids a better capacity to form
tumors in immune-compromised mice. However, an important
distinction should be made between the artificial growth of human
tumors in immune-compromised mice versus tumor progression in
patients. The development of appropriate humanized mice models
might thus, be needed to assess the involvement of these properties
in melanoma progression and metastatic process as it occurs in
patients. Nevertheless, melanoma spheroids constitute an appro-
priate model to study the aggressive molecular and functional
phenotypes of melanoma cells and to identify targets that could
affect their high metastatic potential and poor response to current
therapies, in particular immune-based protocols.
Supporting Information
Figure S1 Melanoma spheroid cells display higher
capacity to differentiate under mesenchymal lineages:
A. Adipogenic differentiation of SLM8 melanoma adherent (MA)
cells and spheroid (MS) cells was assessed by Oil Red O staining
(magnification 6100). B. Osteogenic differentiation of Mela1
adherent (MA) cells and spheroid (MS) cells was assessed by
alkaline phosphatase (AP) activity detection (magnification 610).
(TIF)
Figure S2 Melanoma spheroids and their adherent
counterparts display no side-population: Drug efflux
activity of adherent and spheroid cells was measured by their
ability to exclude the Hoechst dye as previously described
(Grichnik JM, 2006, J. Invest Dermatol 126:142; Goodell MA et
al, 1996, J Exp Med 183:1797). Dissociated SLM8 adherent (MA)
or spheroid (MS) cells were resuspended at 10
6 cells/ml in pre-
warmed DMEM medium supplemented with 3% FBS and divided
into two portions. A portion was treated with 50 mM Verapamil
(Verapamil (+)) and the other was left untreated (Verapamil (2)).
Verapamil is a known blocker of drug efflux. Both portions were
incubated in DMEM medium with 2.5 mg/ml Hoechst 33342 for
90 minutes at 37uC. After incubation the cells were washed in cold
PBS and kept on ice for 5 minutes. All further proceedings were
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discriminate dead versus live cells propidium iodide (PI) (2 mg/ml)
was added to the suspended cells 5 minutes before FACS analysis
for Hoechst 33342 efflux. The Hoechst 33342 dye was excited at
355 nm ultraviolet and the resultant fluorescence was measured at
two wavelengths, 460 and 670 nm. Very few cells were found in
the side-population (SP) that includes the cells that efficiently
excluded the Hoechst dye. The number of cells (adherent and
spheroid) in this region was similar when cells were incubated or
not with Verapamil. Thus, SLM8 cells whether adherent or
spheroid, do not display dye efflux activity. Similar results were
observed with Mela1 adherent and spheroid cells.
(TIF)
Figure S3 The expression of ABCB5 by SLM8 and Mela1
adherent and spheroid cells. A. The expression of ABCB5 by
SLM8 and Mela1 spheroid (MS) and adherent (MA) cells was
analyzed by western blot using goat polyclonal anti-ABCB5
antibody (ABCB5 (N-13): sc-104019, Santa Cruz Biotechnology)
detecting a fragment of approximately 89 kDa. Extracts from
Skmel5 melanoma cells and K562 leukemia cells both reported to
be positive for ABCB5 by real-time PCR (Frank et al, Cancer Res,
65:4320, 2005; Lehne et al, Leuk Res, 33:1379, 2009) were used as
controls. Re-blotting with anti-b-actin ensured equal loading.
Similar results were obtained when western blot analysis was
carried out using goat polyclonal anti-ABCB5 from ProSci (46–620)
(Yang et al, 2010, BMC Cancer, 10:338). B. The expression of
ABCB5 by adherent and spheroid cells as analyzed by immuno-
staining. Dissociated cells from SLM8-MA and SLM8-MS were
incubated with goat polyclonal anti-ABCB5 antibody (ABCB5 (N-
13): sc-104019, Santa Cruz Biotechnology) or with IgG isotype
control, then with FITC-conjugated donkey anti-goat IgG (Santa
Cruz Biotechnologies). Cells were then cytocentrifuged onto slides
(cytospin) and mounted in VECTASHIELD Mounting Media with
DAPI. Images were acquired by immunofluorescence microscopy
on a Zeiss Axiovert 200 M microscope (Zeiss, Germany) equipped
with a Plan Apochromat 636N.A.1.4 oil-immersion objective and
a Axiocam MRM camera (Zeiss) using the Axiovision v4.5.0.0
software (Zeiss). Similar results were obtained with Mela1 cells. C.
The expression of ABCB5 in adherent and spheroid cells as
analyzed by flow cytometry. Dissociated cells from SLM8-MA and
SLM8-MS were incubated with 10 mg/ml rabbit polyclonal anti-
ABCB5 antibody (clone RB16781, Abgent Inc, San Diago, CA) or
IgG isotype control, then with PE-conjugated goat anti-rabbit IgG
(Abgent). Expression was determined by Canto II flow cytometer
(BD Biosciences) and analyzed by Diva and FlowJo softwares.
WM852 melanoma cells were used as positive control (Abgent, data
courtesy of Dr Steve Reuland, University of Colorado, Denver).
Red unfilled histograms (ABCB5) versus black unfilled histograms
for respective isotype control.
(TIF)
Figure S4 Melanoma spheroid and adherent cells have
similar tumorigenic capacity. The capacity of SLM8 and
Mela1 adherent and spheroid cells to form tumors was determined
by subcutaneously injecting groups of 5-week-old female nude mice
(n=3/group) with single-cell inoculates of adherent or spheroid
cells. A log-fold range from cell doses unable to efficiently initiate
tumors (10
4 cells) to doses reported to consistently initiate tumors
(10
6 cells) when melanoma spheroid or melanoma-initiating cells
(Fang, et al., Cancer Res, 2005, 65:9328; Monzani, et al., Eur J
Cancer, 2007, 43:935)(Schatton, et al., Nature, 2008, 451:345) were
transplanted into immune-compromised mice models were assayed.
Tumor formation/growth was monitored for the duration of the
experiments or until disease state required euthanasia. For
secondarytumorassays, adherentor spheroidcells-inducedprimary
tumors were removed after euthanasia at day 90, minced and
subjected to enzymatic digestion. Adherent or spheroid cell-tumor
derived single cells were then injected and monitored as above.
Tumor diameters were measured with calipers and tumor volume
was calculated as (Width)
26(Length)60.5 (Hoek, et al., Cancer Res,
2008, 68:650). A. Incidence of primary and secondary tumors.
Injection of melanoma adherent or spheroid cells from SLM8 or
Mela1 at 10
6 led to the growth of primary tumors in all mice.
Primary tumors were also formed with 1/3 mice injected with 10
5
adherent or spheroid cells from Mela1 but not SLM8, while 10
4
cells inoculates failed to initiate any primary tumors. Injection of
log-fold inoculates of single-cell suspensions from adherent or
spheroid cells-inducedprimarytumorsresulted insecondary tumors
formation at 10
6 and 10
5. B. Growth curves of SLM8 adherent or
spheroid cells-induced primary and secondary tumors. Tumor
growth curves were established by monitoring the volume of both
primary and secondary tumors and are presented as mean values of
tumors volumes obtained with each mice (n=3) 6 SD. Adherent
and spheroid cells-induced primary tumors appeared as small
nodules and reached 100 mm
3 between 30–40 days (upper panel).
For both adherent and spheroid cells secondary tumors appeared
earlier compared with the primary ones and reached 100 mm
3
within only 20 days of injection (lower panels). Similar data were
obtained with tumors induced after injection with Mela1 adherent
and spheroid cells (data not shown). Thus, in our melanoma model,
spheroid and adherent cells behave similarly and show similar
tumor formation capacity.
(TIF)
Figure S5 Common regulated genes in spheroid versus
adherent cells between Mela1 and SLM8 cells.
(TIF)
Table S1 A. Commonly up-regulated genes in Mela1 and
SLM8. B. Commonly down- regulated genes in Mela1 and
SLM8. C. Oppositely-regulated genes in Mela1 and SLM8.
(PDF)
Table S2 Developmental processes regulated genes. List
of the genes regulated in melanoma spheroids (MS)/adherent cells
(MA) involved in developmental processes along with their
respective fold-changes as determined by biological processes
using PANTHER software.
(PDF)
Table S3 Ectoderm, neurogenesis, mesoderm and skel-
etal regulated genes. List of the genes regulated in melanoma
spheroids (MS)/adherent cells (MA) involved in ectoderm,
development, neurogenesis, mesoderm and skeletal development
processes along with their respective fold-changes as determined
by biological processes using PANTHER software.
(PDF)
Table S4 Adhesion/communication regulated genes.
List of the genes regulated in melanoma spheroids (MS)/adherent
cells (MA) involved in cell adhesion/communication processes
along with their respective fold-changes as determined by
biological processes using PANTHER software.
(PDF)
Table S5 Structure/motility regulated genes. List of the
genes regulated in melanoma spheroids (MS)/adherent cells (MA)
involved in cell structure/motility processes along with their
respective fold-changes as determined by biological processes using
PANTHER software.
(PDF)
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PLoS ONE | www.plosone.org 17 April 2011 | Volume 6 | Issue 4 | e18784Table S6 Immunity and defense. List of the genes regulated
in melanoma spheroids (MS)/adherent cells (MA) involved in
immunity and defence processes along with their respective fold-
changes as determined by biological processes using PANTHER
software.
(PDF)
Table S7 Molecular functions regulated genes. List of the
ECM, cell adhesion, cytoskeleton proteins, actin-binding and non-
motor actin-binding regulated genes in melanoma spheroids
(MS)/adherent cells (MA) along with their respective fold-changes
as determined by molecular functions analysis using PANTHER
software.
(PDF)
Table S8 Molecular functions regulated genes. List of the
receptors, other receptors and membrane-bound signaling genes
in melanoma spheroids (MS)/adherent cells (MA) along with their
respective fold-changes as determined by molecular functions
analysis using PANTHER software.
(PDF)
Table S9 Signaling pathways regulated genes. List of the
genes regulated in melanoma spheroids (MS)/adherent cells (MA)
involved in Notch, endothelin and axon guidance signaling along
with their respective fold-changes as determined by signaling
pathways analysis using PANTHER software.
(PDF)
Table S10 Nucleotide sequence of quantitative PCR
primers and corresponding annealing temperatures.
(PDF)
Table S11 Nucleotide sequence of semi-quantitative
PCR primers, corresponding annealing temperatures
and number of cycles performed.
(PDF)
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